<DOC>
	<DOCNO>NCT00592969</DOCNO>
	<brief_summary>This trial conduct South America . The aim trial evaluate efficacy metformin plus biphasic insulin aspart insulin NPH blood glucose control subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Metformin Plus Biphasic Insulin Aspart 30 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treat insulin NPH insulinnaive Body mass index ( BMI ) 35.0 kg/m2 HbA1c 7.511.0 % Participation clinical trial involve investigational product within last 3 month History drug alcohol dependence Known impair hepatic function Known suspect allergy human insulin NPH , insulin aspart component composition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>